leadf
logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals gets green light to continue its Phase 2b/3 coronavirus study from Data and Safety Monitoring Board

The drug repurposing firm said the DSMB had unanimously approved the continuation of the study

Algernon Pharmaceuticals Inc. -
The data from the Phase 2b study will determine the number of patients needed to reach statistical significance in the Phase 3 trial

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) reported more positive news on its multinational Phase 2b/3 human study of Ifenprodil to treat coronavirus (COVID-19).

In a statement on Wednesday, the drug repurposing firm said the external data and safety monitoring board (DSMB) had unanimously approved the continuation of the study.

WATCH: Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll 50th patient

"We are very pleased with the unanimous decision of the DSMB to carry on with the study," said Christopher J. Moreau, chief executive officer of Algernon Pharmaceuticals.

"It confirms what we had previously identified regarding Ifenprodil’s long-standing safety history."

Algernon believes Ifenprodil can reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines, respectively. The latter can result in the so-called cytokine storm contributing to the loss of lung function and ultimately death as has been reported in coronavirus (COVID-19) patients.

With positive preliminary data from the Phase 2b study of a total of 150 patients, the clinical trial will move directly into Phase 3.

The data from the Phase 2b study will determine the number of patients needed to reach statistical significance in the Phase 3 trial.

Patients are randomized in a one-to-one manner and will either be treated using an existing standard of care, or standard of care plus Ifenprodil 60 mg (taken as one 20mg tablet three times a day) for one arm or standard of care plus Ifenprodil 120 mg (taken as two 20 mg tablets three times daily) for two weeks.

Algernon said it would update on a projected completion date of the study, as well as when the read-out of the data can be expected when enrollment in the study reaches 50%.

Contact the author at giles@proactiveinvestors.com

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.31 CAD

CSE:AGN
Market: CSE
Market Cap: $34.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll...

Algernon Pharmaceutical (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has now enrolled a third of their patients in the Phase 2B/3 study of their repurposed drug Ifenprodil. Moreau discusses hitting that mark and also...

3 weeks, 5 days ago

2 min read